US OptionsDetailed Quotes
SLRN241220P2500
- 0.05
- 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume15 Open Interest2.50Strike Price0.00Turnover175.01%IV46.39%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0514Delta0.0540Gamma91.40Leverage Ratio-0.0046Theta-0.0002Rho-4.70Eff Leverage0.0012Vega
Acelyrin Stock Discussion
Sign in to post a comment
$Acelyrin (SLRN.US)$ MT Newswires· 2 mins ago
Acelyrin (SLRN) said Thursday that the global late-stage trial of its treatment izokibep in patients with moderate-to-severe hidradenitis suppurativa yielded statistically significant improvement responses across multiple efficacy endpoints.
Acelyrin (SLRN) said Thursday that the global late-stage trial of its treatment izokibep in patients with moderate-to-severe hidradenitis suppurativa yielded statistically significant improvement responses across multiple efficacy endpoints.
1
$Acelyrin (SLRN.US)$
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused ...
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused ...
ACELYRIN, INC.: A New Horizon in Immunology.
ACELYRIN, INC. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company devoted to accelerating the development and delivery of transformative medicines in the field of immunology. The company is making waves in the medical community with its promising treatments for various immune-related diseases. Founded with a mission to provide life-changing treatment options to patients, ...
ACELYRIN, INC. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company devoted to accelerating the development and delivery of transformative medicines in the field of immunology. The company is making waves in the medical community with its promising treatments for various immune-related diseases. Founded with a mission to provide life-changing treatment options to patients, ...
2
Interesting wick AH. Here are the levels to watch.
Larger Image: tradingview.com...
$Acelyrin (SLRN.US)$
Larger Image: tradingview.com...
$Acelyrin (SLRN.US)$
3
$Acelyrin (SLRN.US)$
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
ACELYRIN, INC. (Nasdaq: SLRN) announced positive Phase 3 data for izokibep in Hidradenitis Suppurativa, meeting the primary endpoint of HiSCR75 at 12 weeks. The company is refocusing its strategy to prioritize lonigutamab development for thyroid eye disease, with plans to initiate a Phase 3 program in Q1...
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
ACELYRIN, INC. (Nasdaq: SLRN) announced positive Phase 3 data for izokibep in Hidradenitis Suppurativa, meeting the primary endpoint of HiSCR75 at 12 weeks. The company is refocusing its strategy to prioritize lonigutamab development for thyroid eye disease, with plans to initiate a Phase 3 program in Q1...
$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
11
1
$Acelyrin (SLRN.US)$ insider buying?good news soon?
No comment yet
LookJock : Junk stocks ran up $0.4 in one day.
Trytosaveabit OP LookJock : The day of this post it went from 4.27 to 5.50! That’s was more than .40? Hehehe!